-
Pioglitazone PPARγ Agonist Research Workflows
2026-09-02
Translate selective PPARγ activation into practical macrophage, beta-cell, metabolic, and neuroinflammation assays. This guide combines formulation controls, DSS-model insights, quantitative readouts, and troubleshooting strategies for more reproducible Pioglitazone research.
-
Linarin, Cyclin A2, and NSCLC Cell-Cycle Arrest
2026-09-01
A 2026 study identifies the Herba Patriniae component linarin as an inhibitor of NSCLC cell growth that promotes G0/G1 arrest, senescence, and apoptosis alongside reduced CCNA2, CCNB1, and CHEK1 expression. By combining network pharmacology with complementary cell-based assays in p53-wild-type and p53-null models, the work provides a mechanistic framework for studying linarin-associated cell-cycle disruption while highlighting the need for in vivo validation.
-
AR Dimer-Interface Antagonists Against CRPC Resistance
2026-09-01
The reference study reports benzo[b]oxepine-4-carboxamide derivatives that target the androgen receptor dimer interface pocket rather than its conventional ligand-binding pocket. Optimization produced Y5, a dual-action antagonist that disrupts AR dimerization, promotes AR degradation, and suppresses drug-resistant prostate cancer models after oral dosing.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-08-31
Hao et al. engineered ICG-MOF-SS-AUNP12, a glutathione-responsive metal–organic framework nanoparticle that combines near-infrared photothermal therapy with PD-1/PD-L1 checkpoint inhibition. The study shows how stimulus-responsive release and immune activation can address the limited ability of single-modality photothermal therapy to control melanoma progression, recurrence, and immune escape.
-
Metal-Free Carbon Nanozymes for ALP Detection
2026-08-31
The reference study develops a metal-free carbon-dot nanozyme assay in which alkaline phosphatase hydrolysis of pyrophosphate relieves catalytic inhibition and generates a colorimetric turn-on signal. Its kinetic analysis identifies pyrophosphate as a noncompetitive inhibitor binding at a site distinct from the principal catalytic region, enabling sensitive ALP activity measurement with reduced risk of metal-ion interference.
-
nor-Binaltorphimine dihydrochloride: Circuit Assays
2026-08-30
Explore how nor-Binaltorphimine dihydrochloride can sharpen κ-opioid receptor antagonist assays by separating receptor pharmacology from brain-to-spinal circuit effects. This guide translates a 2024 mechanistic study into practical design, handling, and interpretation decisions for opioid receptor signaling research.
-
10 mM dNTP Mixture: Reliable DNA Synthesis
2026-08-29
Learn how SKU K1041, a defined 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture, can standardize PCR, qPCR, sequencing, and DNA synthesis steps associated with cell-based viability and cytotoxicity studies. The article separates direct cell-assay biology from downstream nucleic-acid workflow variables and provides practical handling, interpretation, and vendor-selection guidance.
-
Itraconazole for Candida Biofilm Research
2026-08-28
Itraconazole combines triazole antifungal activity with CYP3A4, hedgehog, and angiogenesis-related research utility. This guide translates PP2A–autophagy findings in Candida albicans biofilms into practical assay designs, concentration planning, and troubleshooting workflows.
-
Morning Training Improves Endurance Adaptation in Mice
2026-08-28
Hesketh et al. show that endurance-training time influences the magnitude and efficiency of adaptation in female mice, not merely the time at which performance is tested. Early-active-phase training produced a stronger improvement and distinct skeletal-muscle adaptations despite lower absolute workloads, providing a framework for circadian exercise studies and metabolic phenotyping.
-
CHI3L1-IN-5: Identity-Aware CNS Assay Design
2026-08-27
CHI3L1-IN-5 (Compound Z17) is a CNS-penetrant tool for studying CHI3L1-driven inflammation, astrocyte Aβ handling, and lysosomal recovery. This article adds an identity-aware framework for separating product-specific evidence from lessons derived from a similarly named but mechanistically distinct ALDH2 study.
-
Hoechst 33342 in Translational HPH Research
2026-08-27
Hoechst 33342 is more than a nuclear label: used with disciplined controls, it can convert changes in nuclear architecture into a quantitative bridge between endothelial–smooth muscle crosstalk and translational cell biology. This article connects its mechanism and workflow design to the SP1/ADAM10/DRP1 axis reported in hypoxia pulmonary hypertension while clearly defining what the dye can—and cannot—prove.
-
Intestinal Stretch, Weight Loss, and Satiety
2026-08-26
The reference study shows that intestinal stretch is an independent regulator of acute food intake and oral glucose tolerance, and that obesity weakens this response. Both dietary and surgical weight loss restored stretch-induced satiety signaling, highlighting a mechanical gut–brain pathway that complements, but does not depend on, classical GLP-1 signaling.
-
Validated HPLC Analysis of Trelagliptin Succinate
2026-08-26
This 2018 European Journal of Pharmaceutical Sciences study developed and validated a stability-indicating HPLC method for trelagliptin succinate and eight potential process-related impurities. Its combination of chromatographic separation, forced-degradation testing, and UHPLC–high-resolution tandem mass spectrometry provides a practical framework for pharmaceutical quality control and reproducible diabetes mellitus research workflows.
-
Nanobody-TurboID Maps the CD38 Surfaceome
2026-08-25
Feng and colleagues developed nanobody-targeted TurboID (NBID) to profile proteins positioned near CD38 on living cell surfaces. Integrated proteomics, microscopy, SILAC, and migration assays identified a CD38-associated adhesion network that links tumor-cell membrane organization with tumor–endothelial interactions.
-
Imatinib hydrochloride: Assay Workflows
2026-08-25
This scenario-based guide helps researchers interpret viability and proliferation results when using Imatinib hydrochloride, including SKU A3487, across CML and GIST models. It connects target-level potency, DMSO handling, controls, and vendor-selection criteria to practical assay decisions.